Biolase Buy Rating Affirmed Amid Growth Opportunities and Proactive Cost Management
Maxim Group Downgrades Biolase (BIOL) to a Hold
Biolase Analyst Ratings
Biolase Analyst Ratings
Biolase's Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating
Biolase Analyst Ratings
Maxim Group Reaffirms Their Buy Rating on Biolase (BIOL)
Positive Clinical Trial Results and Successful Cost Optimization Initiatives Bolster Buy Rating for Biolase Despite Lowered Price Target
Positive McGuire Study Results Boost Biolase's Market Potential and Justify Buy Rating
Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)
Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating
Lake Street Maintains Buy on Biolase, Lowers Price Target to $0.4
Maxim Group Maintains Buy on Biolase, Lowers Price Target to $1
Lake Street Remains a Buy on Biolase (BIOL)
Benchmark Reiterates Speculative Buy on Biolase, Maintains $2 Price Target
Lake Street Assumes Biolase at Buy, Announces Price Target of $1.5
Biolase Analyst Ratings
Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)
Maxim Group Remains a Buy on Biolase (BIOL)
No Data